BioLife Solutions, Inc. (NASDAQ:BLFS) CMO Sells $162,760.00 in Stock
BioLife Solutions, Inc. (NASDAQ:BLFS) CMO Sells $162,760.00 in Stock
BioLife Solutions, Inc. (NASDAQ:BLFS – Get Rating) CMO Todd Berard sold 6,500 shares of the company's stock in a transaction dated Wednesday, January 18th. The stock was sold at an average price of $25.04, for a total value of $162,760.00. Following the sale, the chief marketing officer now owns 119,265 shares in the company, valued at approximately $2,986,395.60. The sale was disclosed in a filing with the SEC, which is available through the SEC website.
生物生命解決方案公司(納斯達克代碼：BLFS-GET Rating)首席營銷官託德·貝拉德在日期為1月18日星期三的交易中出售了6,500股該公司股票。這隻股票的平均售價為25.04美元，總價值為162,760.00美元。出售後，首席營銷官現在擁有119,265股公司股票，價值約2,986,395.60美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的，該文件可通過美國證券交易委員會網站.
Todd Berard also recently made the following trade(s):
託德·貝拉德最近還進行了以下交易：
- On Wednesday, December 28th, Todd Berard sold 501 shares of BioLife Solutions stock. The stock was sold at an average price of $16.90, for a total value of $8,466.90.
- On Thursday, November 10th, Todd Berard sold 50 shares of BioLife Solutions stock. The shares were sold at an average price of $23.16, for a total value of $1,158.00.
- 12月28日，星期三，託德·貝拉德出售了501股BioLife Solutions股票。這隻股票的平均售價為16.90美元，總價值為8466.90美元。
- 11月10日，星期四，託德·貝拉德出售了50股BioLife Solutions的股票。這些股票的平均價格為23.16美元，總價值為1158.00美元。
BioLife Solutions Trading Up 2.4 %
BioLife Solutions股價上漲2.4%
NASDAQ:BLFS opened at $24.45 on Monday. The stock's 50 day moving average price is $20.35 and its 200 day moving average price is $21.18. The company has a market capitalization of $1.05 billion, a PE ratio of -9.86 and a beta of 1.75. The company has a quick ratio of 2.76, a current ratio of 3.68 and a debt-to-equity ratio of 0.06. BioLife Solutions, Inc. has a 52-week low of $10.40 and a 52-week high of $31.11.
納斯達克：週一開盤報24.45美元。該股的50日移動均線價格為20.35美元，200日移動均線價格為21.18美元。該公司市值10.5億美元，市盈率為-9.86，貝塔係數為1.75。該公司的速動比率為2.76，流動比率為3.68，債務權益比為0.06。BioLife Solutions，Inc.的股價為10.40美元，為52周低點，52周高點為31.11美元。
Institutional Trading of BioLife Solutions
生物生命解決方案的制度性交易
A number of hedge funds have recently added to or reduced their stakes in the stock. Public Sector Pension Investment Board lifted its position in BioLife Solutions by 1.0% during the 2nd quarter. Public Sector Pension Investment Board now owns 56,525 shares of the medical equipment provider's stock worth $781,000 after acquiring an additional 565 shares during the period. Texas Permanent School Fund lifted its position in BioLife Solutions by 3.0% during the 2nd quarter. Texas Permanent School Fund now owns 21,901 shares of the medical equipment provider's stock worth $302,000 after acquiring an additional 642 shares during the period. Macquarie Group Ltd. lifted its position in BioLife Solutions by 1.1% during the 2nd quarter. Macquarie Group Ltd. now owns 73,437 shares of the medical equipment provider's stock worth $1,014,000 after acquiring an additional 766 shares during the period. Mutual of America Capital Management LLC lifted its position in BioLife Solutions by 18.7% during the 2nd quarter. Mutual of America Capital Management LLC now owns 5,128 shares of the medical equipment provider's stock worth $71,000 after acquiring an additional 808 shares during the period. Finally, Jane Street Group LLC lifted its position in BioLife Solutions by 6.9% during the 1st quarter. Jane Street Group LLC now owns 13,377 shares of the medical equipment provider's stock worth $304,000 after acquiring an additional 858 shares during the period. 89.82% of the stock is owned by institutional investors and hedge funds.
一些對衝基金最近增持或減持了該股。公共部門養老金投資委員會在第二季度將其在BioLife Solutions的頭寸提高了1.0%。公共部門養老金投資委員會現在擁有這家醫療設備提供商的56,525股股票，價值78.1萬美元，在此期間又購買了565股。德克薩斯永久學校基金在第二季度將其在BioLife Solutions的頭寸提高了3.0%。德克薩斯永久學校基金在此期間額外購買了642股，現在擁有21,901股這家醫療設備提供商的股票，價值30.2萬美元。麥格理集團(Macquarie Group Ltd.)在第二季度將其在BioLife Solutions的頭寸提高了1.1%。麥格理集團(Macquarie Group Ltd.)在此期間增持了766股，目前持有73,437股這家醫療設備供應商的股票，價值1,014,000美元。美國互惠資本管理公司在第二季度將其在BioLife Solutions的頭寸提高了18.7%。美國互惠資本管理有限責任公司在此期間額外收購了808股，現在擁有這家醫療設備提供商價值71,000美元的5,128股股票。最後，簡街集團在第一季度將其在BioLife Solutions的頭寸提高了6.9%。簡街集團現在擁有這家醫療設備提供商13,377股股票，價值304,000美元，在此期間又購買了858股。89.82%的股票由機構投資者和對衝基金持有。
Wall Street Analysts Forecast Growth
華爾街分析師預測經濟增長
A number of research analysts have recently commented on BLFS shares. Stephens dropped their price objective on BioLife Solutions to $31.00 in a report on Wednesday, November 16th. StockNews.com upgraded BioLife Solutions to a "sell" rating in a report on Monday, November 21st.
一些研究分析師最近對BLFS的股票發表了評論。斯蒂芬斯在11月16日星期三的一份報告中將BioLife Solutions的目標價下調至31.00美元。在11月21日星期一的一份報告中，StockNews.com將BioLife Solutions的評級上調至“賣出”。
BioLife Solutions Company Profile
BioLife Solutions公司簡介
(Get Rating)
(獲取評級)
BioLife Solutions, Inc develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.
BioLife Solutions，Inc.為美國、加拿大、歐洲、中東、非洲和國際上的細胞和基因治療行業開發、製造和提供生物生產工具和服務。該公司的產品用於基礎和應用研究，以及基於生物的療法的商業製造。
Further Reading
進一步閲讀
- Get a free copy of the StockNews.com research report on BioLife Solutions (BLFS)
- CVS Health is Growing into an Integrated Healthcare Organization
- NVIDIA Outlook Improving: Watchlist Candidate for 2023
- Is C3.ai Stock a ChatGPT Artificial Intelligence Play?
- Which Wireless Stock Should You Buy in 2023?
- Is Virgin Galactic Stock Preparing for Lift-Off?
- 免費獲取StockNews.com關於BioLife解決方案的研究報告(BLFS)
- CVS Health正在成長為一家綜合醫療保健組織
- NVIDIA前景改善：2023年候選觀察名單
- C3.ai Stock是ChatGPT人工智能的玩法嗎？
- 2023年你應該購買哪些無線股票？
- 維珍銀河股票準備起飛了嗎？
Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.
每日收到有關BioLife解決方案的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對BioLife Solutions和相關公司的最新新聞和分析師評級的每日簡要摘要。